Funder: The Mark Foundation for Cancer Research
Due Dates (Anticipated): January 2026: Letter of Intent (Glioblastoma RFP) | February 2026: Letter of Intent (IDPs & Cancer RFP) | April 2026: Letter of Intent (Follicular Lymphoma RFP) | July 2026: Full application (Follicular Lymphoma RFP)
Funding Amounts: Up to $250,000 for 12 months (standard ASPIRE); up to $350,000 for 24 months (Follicular Lymphoma RFP); indirect costs capped at 10%.
Summary: Supports high-risk, high-reward cancer research projects addressing feasibility or proof-of-concept questions across basic, translational, clinical, and technology domains.
Key Information: All dates are projected; specific RFP topics and eligibility vary—review program pages for current calls.